Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cytek Biosciences, Inc. (CTKB : NSDQ)
 
 • Company Description   
Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif.

Number of Employees: 502

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.82 Daily Weekly Monthly
20 Day Moving Average: 819,456 shares
Shares Outstanding: 134.31 (millions)
Market Capitalization: $1,318.95 (millions)
Beta:
52 Week High: $28.70
52 Week Low: $7.38
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.10% 12.75%
12 Week -25.61% -18.21%
Year To Date -39.83% -26.48%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
47215 Lakeview Blvd
-
Fremont,CA 94538
USA
ph: 877-922-9835
fax: -
investors@cytekbio.com https://cytekbio.com
 
 • General Corporate Information   
Officers
Wenbin Jiang - President; Chief Executive Officer and Director
Patrik Jeanmonod - Chief Financial Officer
Ming Yan - Chief Technology Officer and Director
Jack Ball - Director
Feng Deng - Director

Peer Information
Cytek Biosciences, Inc. (CORR.)
Cytek Biosciences, Inc. (RSPI)
Cytek Biosciences, Inc. (CGXP)
Cytek Biosciences, Inc. (BGEN)
Cytek Biosciences, Inc. (GTBP)
Cytek Biosciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 23285D109
SIC: 3826
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 09/01/22
Share - Related Items
Shares Outstanding: 134.31
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $1,318.95 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.02 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.09 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/01/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 109.11
Trailing 12 Months: 327.33
PEG Ratio: -
Price Ratios
Price/Book: 3.24
Price/Cash Flow: 154.20
Price / Sales: 9.51
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -140.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -9.85%
ROE
03/31/22 - 1.78
12/31/21 - 3.60
09/30/21 - -
ROA
03/31/22 - 1.31
12/31/21 - 2.50
09/30/21 - -
Current Ratio
03/31/22 - 10.26
12/31/21 - 13.01
09/30/21 - 14.65
Quick Ratio
03/31/22 - 9.37
12/31/21 - 12.04
09/30/21 - 13.74
Operating Margin
03/31/22 - 3.86
12/31/21 - 5.62
09/30/21 - -
Net Margin
03/31/22 - 0.98
12/31/21 - 2.73
09/30/21 - -
Pre-Tax Margin
03/31/22 - 1.79
12/31/21 - 4.64
09/30/21 - -
Book Value
03/31/22 - 3.03
12/31/21 - 3.03
09/30/21 - 3.02
Inventory Turnover
03/31/22 - 1.73
12/31/21 - 1.70
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©